High Dose Inactivated Influenza Vaccine — Competitive Intelligence Brief

High Dose Inactivated Influenza Vaccine (High Dose Inactivated Influenza Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

marketed vaccine Immunology Biologic

Target snapshot

High Dose Inactivated Influenza Vaccine (High Dose Inactivated Influenza Vaccine) — University of Pittsburgh. A high-dose inactivated influenza vaccine stimulates a stronger immune response by delivering increased antigen content to enhance antibody production and cellular immunity against influenza viruses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
High Dose Inactivated Influenza Vaccine TARGET	High Dose Inactivated Influenza Vaccine	University of Pittsburgh	marketed	vaccine
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
AVA	AVA	Emergent BioSolutions	marketed	Inactivated bacterial vaccine	Bacillus anthracis protective antigen (PA) and lethal factor
Meningococcal A+C vaccine	Meningococcal A+C vaccine	Sanofi Pasteur, a Sanofi Company	marketed	Polysaccharide conjugate vaccine	Neisseria meningitidis serogroups A and C capsular polysaccharides
FluMist trivalent (2015-2016)	FluMist trivalent (2015-2016)	MedImmune LLC	marketed	Live attenuated influenza vaccine
Pandemic influenza A/H1N1 vaccine	Pandemic influenza A/H1N1 vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (vaccine class)

1. Pfizer · 20 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
3. GlaxoSmithKline · 12 drugs in this class
4. Merck Sharp & Dohme LLC · 12 drugs in this class
5. Centers for Disease Control and Prevention · 9 drugs in this class
6. Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
7. Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
8. Beijing Center for Disease Control and Prevention · 6 drugs in this class
9. International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
10. Sinovac Biotech Co., Ltd · 4 drugs in this class